Phase 2 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and teenagers between 6 and 18 years old (inclusive)
- People whose kidneys are working at a reduced level, measured by a specific kidney function test called GFR, falling between 15 and 59 ml/min per 1.73 m² using a formula designed for children
- People whose blood phosphate level is 5.9 mg/dl or below
- People whose blood iron storage levels (ferritin below 500 ng/ml and TSAT below 50%) are within the required range
- People taking growth hormone, certain vitamin D supplements, iron, or red blood cell stimulating medicines, as long as the doses of those treatments have been stable for at least 2 weeks before the screening visit
- People who are able to swallow tablets
- People who are able to eat at least two meals a day
- People who, in the opinion of the trial doctor, are willing and able to follow the study treatment plan and recommendations
Who may not be able to join:
- People who are currently taking phosphate binder medications
- People with a known allergy to any ingredient (including non-medical ingredients) in both the study product and the placebo
- People who have a documented history of intestinal malabsorption, inflammatory bowel disease, or Crohn's Disease
- People for whom dialysis or a kidney transplant is expected to be needed within the next 6 months
- People who are currently taking or plan to take medicines that suppress the immune system
- People who have previously received a solid organ transplant (such as a kidney, liver, or heart)
- People who received a bone marrow transplant within the two years before the screening visit
- People who are currently pregnant or breastfeeding, or females who have started their menstrual periods, unless highly effective contraception is being used as specified in the trial protocol (confirm with trial site)
- People who are already taking part in another interventional clinical trial (participation in observational studies is allowed)
- People who, in the opinion of the trial doctor, have a history of not following medical treatments as directed
- People with a condition called cystinosis
- People with a condition called Fanconi syndrome
- People with hemochromatosis, or whose blood test results suggest possible hemochromatosis or another condition involving excess iron in the body
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Isidro B Salusky, MD, University of California, Los Angeles
Phone: 310-7943144
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
iFGF23 levels; Safety of Ferric Citrate; Tolerability of Ferric Citrate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.